LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial - Robinson, J G; Nedergaard, B S; Rogers, W J (JAMA, 2014)
et al.